Kangstem Biotech acquires approval of world’s first stem cell treatment for atopic dermatitis
Kangstem Biotech(CEO Tae-Hwa Lee) announced on the 5th that it acquired IND(Investigational New Drug) of a Phase III clinical trial for ‘Furestem-AD,’ the world’s first and only stem cell therapeutic product for atopic dermatitis.
In the Phase III clinical trial, total 194 patients with severe a...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.